isorenieratene: isolated from Brevibacterium linens; structure in first source
ID Source | ID |
---|---|
PubMed CID | 9984420 |
CHEBI ID | 80196 |
MeSH ID | M0580384 |
Synonym |
---|
isorenieratene/ (leprotene) |
LMPR01070124 |
isorenieratene |
524-01-6 |
CHEBI:80196 |
DTXSID60433638 |
phi,phi-carotene |
Q10859788 |
1,2,4-trimethyl-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-3,7,12,16-tetramethyl-18-(2,3,6-trimethylphenyl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]benzene |
leprotene, all-trans |
1,3,5,7,9,11,13,15,17-octadecanonaene, 3,7,12,16-tetramethyl-1,18-bis(2,3,6-trimethylphenyl)-, (all-e)- |
streptoxanthin |
leprotene |
l8x7k8799e , |
benzene, 1,1'-(3,7,12,16-tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis(2,3,6-trimethyl-, (all-e)- |
streptoxanthin, all-trans- |
(all-e)-1,1'-(3,7,12,16-tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis(2,3,6-trimethylbenzene) |
unii-l8x7k8799e |
Class | Description |
---|---|
diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
carotenoid phi-end group | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
isorenieratene biosynthesis I (actinobacteria) | 0 | 5 |
isorenieratene biosynthesis I (actinobacteria) | 2 | 6 |
isorenieratene biosynthesis II (Chlorobiaceae) | 2 | 3 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 3 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.33) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |